tbuckley/cabot-search huggingface dataset:
Diabetes, New York
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
JAMA Cardiology
Authors: Phil Fontanarosa, Annette Flanagin, Brenda Gregoline, Tracy Frey, Iris Lo, Kevin Brown, Amanda Ehrhardt, M Newman, Suzanne Walker, Connie Manno Senior, Sara Billings, Timothy Gray, Juliet Orellana, Paul Ruich, Kirby Snell, Catherine Alden, Stephanie Beckmeyer, Jane Calayag, Jan Clavey, Mary Coerver-Connolly, Heather Flint, Bernadette Hromin, Paul Jaworski, Laura King, Regina Lilly, Jenny Mackay, Molly O'donnell, Charon Pierson, Lori Ryan, Thressa Smith, Divya Sreekumar, Annette Theuring, Donna Thordsen, Christine Tilles, Caroline Woods, Editorial Assistant, Wanda Hill, Larry Bryant, Jacob Kendall-Taylor, Monica Managers, Fanny Staff, Anna Brown, Lee Bukowski, Lenette Calibeo, Tosca Gardner-Gullens, Erin Hall, Rachell Kato, Kenneth Lozano, Caroline Otani, Angelia Sietmann, Michael Berkwits, Eric Butkus, Jesse Mcquarters, Elena Guobyte, Emily Ling, Daniel Morrow, Social Media, Eman Hassaballa, Reuben Rios, Mary Ferkaluk, Karen Bucher, Andy Rekito, Nick Reback, Lohitha Kethu, David Song, Deputy Livingston, Thomas Cole, Administration Director, Marla Jeff, Deanna Willis, Yolanda Davis, Joseph Thornton, Deanna Bellandi, Jim Periodical, Thomas Easley, Brian Shields, Karen Adams-Taylor, Paul Gee, Monica Smith, Euwanaha Joiner-Smith, Joshua Lane, Cindy Rendlen, Ellen Yoshihara, Annissa Zak, Circulation Services, Julie Burton, Ronna Hewitt, Mary Sieck, Geneine Someren, Jamaal Vargas, Mike Bujewski, Nathan Mitre, Digital Production, Regina Brownlee, Amanda Camino, Brenda Chandler-Grayer, Emily Dunn, Amy Evers, Maleeka Holden, Teri Hutchison, Dan Knowles, Joshua Lampinen, Natalie Marsh, Patricia Panek, Marla Seidell, La Son, Diggs Sledge, Julian Graphics, Joe Amft, James Collver, Maria Duda, Fred Furtner, Carolyn Hall, Maria Kowalkowski, Proofreading Carol, Joy Farrell, Maria Giannini, Sasha Grossman, Judith Literskis, Teresa Omiotek, Michael Ryder, James Madara, Howard Bauchner, Robert Bonow, Patrick O'gara, Marc Sabatine, Clyde Boston, Michael Pencina, Carolina North, Adrian Hernandez, Mhs Durham, North Carolina, Mark Huff Man, Ajay Kirtane, New York, Roxana Mehran, Ann Navar, Carolina Christopher, J O'donnell, Massachusetts Boston, J Sanjiv, Mintu Shah, Gregg Fonarow, Los Angeles, Elizabeth Mcnally, Laine Thomas, Akhil Narang, Julia Getts, Eugene Braunwald, Robert Califf, Judith Hochman, Donald Lloyd-Jones, Scm Chicago, Michael Parmacek, Daniel Simon, Sidney Smith, Chapel Hill, Carolina Douglas, E Vaughan, Myron Weisfeldt, Maryland Douglas, P Zipes, Paul Armstrong, Shinya Goto, Peter Liu, Renato Lopes, Carolina Maseri, Dorairaj Prabhakaran, Hugh Watkins, Harvey White, Habib Yacoub
Journal: JAMA Cardiology (2020)
American College of Physicians Medical Oncology Review Course
Journal: JNCI Journal of the National Cancer Institute (1983)

American College of Physicians Medical Oncology Review Course Get access JNCI: Journal of the National Cancer Institute, Volume 70, Issue 5, May 1983, Page 988, https://doi.org/10.1093/jnci/70.5.988-f Published: 01 May 1983
Ohio State Medical Society.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract P270: Associations of Lipoprotein-associated Phospholipase A <sub>2</sub> Mass and Activity with Coronary Artery Calcium: The Multi-Ethnic Study of Atherosclerosis (MESA)
Authors: Nancy S Jenny, Robyn McClelland, Neal Jorgensen, Parveen Garg, Gregory Burke, Michael Criqui, Philip Greenland, Robert Rosenson, David Siscovick, Mary Cushman
Journal: Circulation (2013)

Background: Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) is an inflammatory enzyme localized in atherosclerotic lesions. However, associations of Lp-PLA 2 with coronary artery calcium (CAC), used as a marker of lesion progression, have not been extensively studied and may vary by sex and type of Lp-PLA 2 assay. Methods: We examined these associations in 5486 White, Black, Chinese and Hispanic men and women in the Multi-Ethnic Study of Atherosclerosis (MESA). At baseline, mean age was 62 years; all were free of clinical cardiovascular disease. CAC, by cardiac computed tomography, was assessed at baseline (2000-02) and follow-up; half the cohort at exam 2 (2002-04), the remainder at exam 3 (2004-05). 2758 had CAC (Agatston score&gt;0) at baseline; of those with no baseline CAC, 372 (13.6%) had incident CAC (CAC&gt;0) at follow-up. Lp-PLA 2 mass and activity were measured by immunoassay and enzymatic assay, respectively. Longitudinal models were adjusted for age, sex, ethnicity, smoking, diabetes, obesity, total and HDL cholesterol, blood pressure, hypertension, lipid-lowering medications and time between CAC measures. Results: Each standard deviation (SD 36.5 nmol/min/ml) increase in Lp-PLA 2 activity was associated with CAC presence (prevalence ratio 1.03; p=0.01) in the whole group at baseline and incidence in those with no CAC at baseline (odds ratio 1.17; p=0.02). Activity was not associated with CAC progression (increase in Agatston score over time) in the whole group (β=1.32; p&gt;0.4). Lp-PLA 2 mass was not associated with CAC presence or incidence (SD 45.6 ng/ml; associations p&gt;0.2). The only association that differed significantly by sex was that for mass and progression (p interaction 0.01). Mass was associated with CAC progression in women (β=4.99; p=0.004) but not men (β=-0.20; p&gt;0.9). Conclusions: In this multi-ethnic cohort, associations of Lp-PLA 2 with CAC varied by sex and Lp-PLA 2 assay type. Lp-PLA 2 activity was associated with CAC presence and incidence, but not progression. Mass was associated with CAC progression in women only. Additional research is needed to support the clinical utility of Lp-PLA 2 in monitoring atherosclerosis progression.
Chronic Lead Absorption
Authors: Philip J. Landrigan
Journal: JAMA (1975)

Three cases of mild lead poisoning were discovered among instructors at an indoor pistol range. These cases were characterized by blood lead levels greater than 100μg/100 ml, free erythrocyte protoporphyrin levels greater than 450μg/100 ml of red blood cells, abdominal pain, and, in one instance, by slowing of motor and sensory nerve conduction velocity. Exposure to airborne lead produced during revolver-firing and bullet-molding accounted for the lead absorption. Ventilation in the range was inadequate. (<i>JAMA</i>234:394-397, 1975)
Triiodothyronine and cardiac surgery
Authors: B. F. Boylston
Journal: JAMA (1996)

<h3>To the Editor.</h3> —The article by Dr Bennett-Guerrero and colleagues<sup>1</sup>gives the impression that triiodothyronine (T<sub>3</sub>) is being considered for routine use in the community as an inotropic agent after coronary artery bypass surgery. My hospital's cost for T<sub>3</sub>is $900, and the cost for dopamine is $15. Dopamine will always be preferential on a routine basis on cost alone. Animal data show that T<sub>3</sub>is most beneficial after severe global myocardial ischemia.<sup>2-4</sup>Yet the study by Bennett-Guerrero et al excluded all preoperative patients requiring intraaortic balloon pump or inotropic support. Essentially, the group of patients most likely to benefit were excluded from the trial. The comparison of a hormone to an inotropic agent is the comparison of apples to oranges. The mechanism of action is different. No one is sure how T<sub>3</sub>works on myocardial cell function. I agree that dopamine is the
Incidence and significance of candiduria
Authors: P. K. Goldberg
Journal: JAMA (1979)

The 100,000 colony count has been used without careful evaluation for the diagnosis of renal candidiasis. Therefore, a prospective study was done on 1,004 urine samples from patients without signs of candidiasis to determine the incidence of candiduria and<i>Candida</i>colony counts. These were compared with colony counts from histologically proved cases of renal candidiasis. The incidence of candiduria varied from a low of 4% in men to a high of 39% in girls during their second week of antibiotic therapy. The overall mean colony count was 1,292±1,500. The mean colony count in clean-catch urine specimens from six proved cases of renal candidiasis was 23,750±12,311. The difference in colony counts from proved and unproved cases is statistically significant. Counts greater than 10,000<i>Candida</i>organisms per milliliter require further investigation. (<i>JAMA</i>241:582-584, 1979)
Addresses and Essays.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Government Services
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pneumocystis carinii Pneumonia
Authors: NICK J. MANSOUR
Journal: Annals of Internal Medicine (1970)

Letters and Comments1 August 1970Pneumocystis carinii PneumoniaNICK J. MANSOUR, M.D.NICK J. MANSOUR, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-73-2-342 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: The onset of current interest and enthusiasm in treatment of malignant diseases has brought some astounding results. Many patients who at one time were written off as lost are now being given good useful lives. But any new form of therapy opens a Pandora's box of other problems. One such problem is the diffuse interstitial pneumonia caused by the protozoanPneumocystis carinii. The disease can be and more often than not is fatal; and early therapy is imperative, as it can be curative. Dr. Goodell and associates (1) attempt to outline some of the prime features, but...Reference1. GOODELLJACOBSPOWELL BJR: Pneumocystis carinii: the spectrum of diffuse interstitial pneumonia in patients with neoplastic diseases. Ann Intern Med 72:337-340, 1970 LinkGoogle Scholar1. VOGELCOHENPOWELL CMR: Pneumocystis carinii pneumonia. Ann Intern Med 68:97-108, 1968 LinkGoogle Scholar2. DEVITAEMMERLEVINE VMA: Pneumocystis carinii pneumonia: the successful diagnosis and treatment of two patients with associated malignancy. New Eng J Med 280: 287-291, 1969 CrossrefMedlineGoogle Scholar3. FRENKELGOODSHULTZ JJJ: Latent pneumocystis infection in rats, relapse and chemotherapy. Lab Invest 15: 1559, 1966 MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: NICK J. MANSOUR, M.D.Affiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byIdentification of Pneumocystis jirovecii with Fluorescence In-Situ Hybridization (FISH) in Patient Samples—A Proof-of-PrinciplePneumocystis — A Genus Long Known, But with Relationships Only Recently AppreciatedPneumocystis 1 August 1970Volume 73, Issue 2Page: 342-343KeywordsInterstitial lung diseasesPneumocystisPneumocystis carinii pneumoniaProtozoans ePublished: 1 December 2008 Issue Published: 1 August 1970 PDF downloadLoading ...
La Methode Brown-Sequard, Traite D' Histotherapie. La thérapeutique des Tissus, Compendium des Médications par les extraits d'organes animaux, par le Dr. M. Bra. Ouvrage précédé de letters et préfaces de MM. les Professeurs Constantin Paul, Mendel Ewald, Bruns, Emminghaus et Byrom Bramwell, accompagné de 72 gravures. Paper.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
The relation between hospital experience and mortality for patients with AIDS
Authors: V. E. Stone
Journal: JAMA (1992)

<h3>Objective.</h3> —To determine whether there is an association between mortality and hospital acquired immune deficiency syndrome (AIDS) experience for all AIDS-related diagnoses, and to determine whether the association is explained by differences in severity of illness, earlier discharge of terminally ill patients, or differences in resource use. <h3>Design and Setting.</h3> —Population-based statewide cohort study. All hospitalizations identified for a cohort of AIDS patients diagnosed during 1987 in 40 Massachusetts hospitals were included. <h3>Patients.</h3> —All women and all male intravenous drug users (n=151), and a random sample of all male non—intravenous drug users diagnosed with AIDS during 1987 in Massachusetts (n=149). <h3>Main Outcome Measures.</h3> —Primary end points studied were (1) inpatient mortality and (2) 30-day mortality. Length of stay, cost, and intensive care unit use were also examined. <h3>Results.</h3> —In 806 hospitalizations at 40 hospitals inpatient mortality was 13.2%. Relative risk of mortality at low AIDS experience hospitals was 2.16 (95% confidence interval, 1.43 to 3.26) compared with high AIDS experience hospitals. When logistic regression was used to control for age, sex, race, human immunodeficiency virus transmission mode, severity, payer, admission type, hospital ownership, and teaching status, low hospital experience with AIDS remained a significant predictor of inpatient mortality (relative risk, 2.92; 95% confidence interval, 1.37 to 6.22). Comparisons of 30-day mortality by hospital AIDS experience yielded similar results. Length of stay and intensive care unit use were also significantly higher at low-experience hospitals after controlling for severity of illness (<i>P</i>&lt;.05). <h3>Conclusions.</h3> —We conclude that mortality of AIDS patients is higher at hospitals with less AIDS experience. This finding is not because of greater severity of illness, differences in discharge patterns of the terminally ill, or less intensive use of resources. (<i>JAMA</i>. 1992;268:2655-2661)
PERCIVALL POTT
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Scientists' Campaign Against the Strategic Defense Initiative
Authors: John B. Kogut
Journal: JAMA (1987)

IN HIS March 1983 speech announcing the Star Wars program (officially called the Strategic Defense Initiative [SDI]), President Reagan called on this nation's scientists and engineers to develop a defensive shield against Soviet land-based nuclear missiles. Therefore, scientists and engineers were placed in a special position to evaluate the program's prospects, and they had a responsibility to respond to the President's call based on their informed assessment of the program. This article documents an unprecedented response to a military program: a national boycott of Star Wars research in which science and engineering professors have pledged neither to solicit nor accept SDI research funds. In each of well over 120 research departments in relevant fields, half or more of the faculty members have joined the boycott. The pledge signers include a clear majority of the nearly 1000 faculty members in the nation's 20 top physics departments. There are over 12 000
Two-way street links ever-smaller world spanned by CDC's epidemiologic efforts
Authors: P. Cotton
Journal: JAMA (1990)

IN the global village, it is CDC physicians who make house calls. "Peace Corps types" is how the CDC's public affairs director, Don Berreth, describes the epidemiologists who hop an international flight at the drop of a hat when asked to assist in solving an out-of-the-ordinary health problem. From the Union Carbide industrial disaster in Bhopal (<i>JAMA</i>. 1985; 253:2001-2013) to the mysterious toxic oil syndrome in Spain, CDC investigators often have been among the first on the scene. Medical emergencies took them to 20 countries on five continents during the past year alone. And, in turn, scientists from around the world come to Atlanta, Ga, for the unique epidemiologic training that the CDC can provide. More than 1000 came from 119 countries in 1989. There may be an occasional cultural clash or diplomatic gaffe, but "our reputation is such that usually an apology will suffice," says Joe Davis, MD, director
Fucosylation index of α-fetoprotein, a possible aid in the early recognition of hepatocellular carcinoma in patients with cirrhosis
Authors: Y Aoyagi
Journal: Hepatology (1993)

We report here on three patients with cirrhosis for whom an early recognition of hepatocellular carcinoma was made possible by the measurement of the degree of fucosylation (fucosylation index) of α-fetoprotein. Increased levels of this index associated with a moderate increment of serum concentration of α-fetoprotein were observed in three patients with cirrhosis who showed no indication of hepatocellular carcinoma by several imaging modalities. Four years after the onset of an increase in the fucosylation index, small hepatocellular carcinoma with a tumor diameter less than 2 cm was revealed in case 1. In cases 2 and 3, small hepatocellular carcinomas were detected 24 mo and 9 mo, respectively, after the first sign of the increase in the index. However, the development to hepatocellular carcinoma was not detected in five patients with cirrhosis in whom continuous increments of serum concentration of α-fetoprotein with low levels of fucosylation index were observed during the prospective follow-up from 3 to 9 yr. These findings indicated that the fucosylation index of α-fetoprotein can be used as an aid in an early recognition of hepatocellular carcinoma, especially in patients with cirrhosis during the follow-up process in which the moderate increment of serum concentration of α-fetoprotein is noted. (HEPATOLOGY 1993;17:50–52.)